Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

A federally commissioned study that concluded even low levels of alcohol consumption may increase the risk of disease and premature death has now been published in a scientific journal after its findings were set aside by the Trump administration.

The study, known as the Alcohol Intake and Health Study, was commissioned as part of an effort to update the United States Dietary Guidelines. Researchers concluded that consuming as little as one alcoholic drink per day could raise the risk of serious illness and mortality.

However, the report was never officially released by the administration and later became the subject of political and industry scrutiny.

Why Was the Study Not Released?

Launched in 2023, the Alcohol Intake and Health Study was overseen by the Substance Abuse and Mental Health Services Administration (SAMHSA).

The review aimed to inform recommendations on alcohol consumption in the next edition of the federal dietary guidelines. But soon the study garnered controversy with some members of Congress and alcohol lobby groups arguing that scientists involved in the review held anti-alcohol views, according to Stat News.

As per a House Oversight Committee report, released in January, the study was "irretrievably flawed". It recommended that federal officials disregard its findings when drafting dietary guidance.

However, researchers involved in the project argued that the findings were sidelined because they conflicted with the interests of the alcohol industry.

What Did The Study Find?

Also read: Is There A Safe Limit For Alcohol Consumption? Major Review Challenges Long-Held Beliefs

After the federal review was shelved, researchers submitted their work independently to the Journal of Studies on Alcohol and Drugs, where it was published following peer review.

The published analysis concluded that even modest alcohol consumption — roughly one drink per day — is associated with increased risks of disease and death.

“These findings are not radical. They are rigorous — and commercially threatening,” wrote Robert Vincent, a former SAMHSA associate administrator for alcohol prevention and treatment policy, in an accompanying editorial.

Vincent, who helped oversee the project, lost his position during broader cuts across federal health agencies last year, the report said.

Notable, the US Department of Health and Human Services (HHS) has stated that the now published article was not the same report reviewed by the government and emphasized that it was not commissioned, approved, or cleared by SAMHSA.

Alcohol Guidance Changed

Read More: X-Men Star Tyler Mane Reveals ‘Super-Rare’ Male Breast Cancer Diagnosis

Federal officials said they reviewed a broad range of scientific evidence when updating the nation's dietary recommendations.

New dietary guidelines released in January marked a significant shift in alcohol messaging. Rather than recommending specific daily limits, the guidance now advises Americans to “consume less alcohol for better overall health.”

According to HHS, the recommendation was based on a separate scientific review rather than the SAMHSA-led report.

For the first time in 20 years, the US Food and Drug Administration (FDA) has added bemotrizinol to the list of permitted sunscreen active ingredients.

Bemotrizinol is the first new active ingredient added to the over-the-counter (OTC) sunscreen monograph since the late 1990s and has been used for years in Europe and Asia.

“As promised in the Trump Administration’s MAHA Strategy Report, HHS is advancing innovation by bringing a new sunscreen ingredient to the US market for the first time in 20 years,” said HHS Secretary Robert F. Kennedy Jr.

“Bemotrizinol has been used safely in Europe for decades, and FDA’s action will increase competition and consumer confidence in sunscreen products.”

On December 11, 2025, the FDA proposed allowing the use of bemotrizinol in sunscreens. The agency finalized the action within seven months of issuing the proposed order.

Bemotrizinol is known to provide stable, long-lasting protection against both types of ultraviolet (UV) rays that can damage the skin. According to the FDA, it is also gentle enough to be used safely by young children.

What Is Bemotrizinol?

Also read: X-Men Star Tyler Mane Reveals ‘Super-Rare’ Male Breast Cancer Diagnosis

Bemotrizinol, also known as BEMT, is a chemical sunscreen filter that absorbs both UVB and UVA rays. The sun emits ultraviolet radiation, which sunscreen products are designed to block.

UVA and UVB rays affect the skin differently. UVA rays are primarily associated with tanning and skin ageing, while UVB rays are more closely linked to sunburn. UVB rays can also be partially blocked by barriers such as windows and clouds.

According to the University of Texas MD Anderson Cancer Center, about 95 per cent of the UV radiation reaching the Earth's surface is UVA, while UVB accounts for the remaining 5 per cent.

Sunscreens protect the skin either by creating a physical barrier using mineral ingredients or by using chemical filters that absorb UV radiation before it reaches the skin. Bemotrizinol belongs to the latter category.

The addition of BEMT is being welcomed by many experts because options that are both highly effective and considered safe remain limited in the US sunscreen market, according to an annual report by the Environmental Working Group (EWG), a nonprofit health and environmental advocacy organization.

Why Is Bemotrizinol Considered Beneficial?

Read More: Confused By Your Cholesterol Report? Here's What LDL And ApoB Really Mean

Bemotrizinol offers several characteristics that make it an effective sunscreen ingredient. It provides broad-spectrum protection against both UVA and UVB radiation and can achieve higher SPF protection at lower concentrations than some other commonly used sunscreen chemicals, according to Certified Laboratories and the FDA.

The ingredient is also photostable, meaning it breaks down more slowly when exposed to sunlight, helping maintain protection for longer periods. Because it is oil-soluble, it can be easily incorporated into creams and lotions.

In addition, bemotrizinol is minimally absorbed through the skin and rarely causes irritation, which is one reason the FDA considers it safe for use in children as young as six months old.

Bemotrizinol Added to OTC

Meanwhile, DSM Nutritional Products, a manufacturer submitted an OTC monograph order request seeking to add bemotrizinol, marketed as Parsol Shield, at concentrations of up to 6 per cent as a new active ingredient in the OTC sunscreen monograph.

“The FDA reviewed the request and proposed to amend the OTC monograph to add bemotrizinol as a sunscreen active ingredient,” the agency said in its announcement.

In December 2025, DSM had announced that, once approved, Parsol Shield would be available for use in sunscreen products in accordance with the monograph requirements.

According to the FDA, OTC monograph drugs such as sunscreens can enter the market without an approved drug application if they meet specific requirements, including permitted active ingredients, uses and dosage limits established under the monograph.

The FDA can modify an OTC monograph through an administrative order, and manufacturers can initiate the process by submitting an OTC monograph order request.

Remember Raghu Ram from the MTV reality show 'Roadies'? The actor and television host recently celebrated 10 years of a smoke-free life and took to Instagram to share his progress with fans. Smoking is injurious to health, and that is a known fact. It is associated with heart disease, cancer, hypertension, and even respiratory difficulties in the future. This habit can turn fatal too if one becomes addicted to nicotine. But for Raghu Ram, this journey ended 10 years ago, and he has never looked back since.

From chain smoker to now

"Iss mahine cigarette chhodkar mujhe pure 10 saal ho gaye hain. Or main aisa waise smoker nhi tha. Main peeta tha din mein 1-2 packets daily. Yani 20-40 cigarettes roz. Par maine bahut koshish ki chhodne ki, lekin addiction hoti hai, chor nhin pate hain log. Main bhi nhin chor paya tha," Raghu said in an Instagram video.

"Aisa chora ki wapas ek bhi kash nahin mara. 10 saal ho gaye hain mereko," he added.

How did Raghu Ram quit smoking?

On his podcast Mencyclopedia in 2023, Raghu Ram revealed that he once smoked 20–40 cigarettes a day for 15 years and then suddenly stopped.

"I smoked 20–40 cigarettes every day for 15 years, and then I just stopped. Cold turkey. And I had not taken a puff of a cigarette in 7 years," he said in his podcast titled How I Won the Longest Battle with My Addiction.

After trying several times to quit, Raghu Ram finally gave up smoking after marrying his wife, Natalie Di Luccio, a Canadian singer, in 2018.

Raghu Ram's 7-step guide to quitting smoking

Here is a simple seven-step guide from the former 'Roadies' host and judge:

1. Decide on a date when you want to quit smoking and announce it to everyone.
2. Overdo it a day or two before that so that you are fully disgusted by the act.
3. List all your smoking triggers in order of severity.
4. Avoid situations that can trigger you during the initial phase when you are struggling with withdrawal symptoms.
5. Once you are through the first two weeks, you can gradually put yourself in trigger situations—from least to most severe—and still manage to resist the urge to smoke.
Exercise regularly, as it makes a significant difference to your cravings.

For every person who has ever quit smoking or wanted to do it

For everyone who has ever quit smoking, the reasons may look different, but they all have two things in common: first, an addiction they are battling; and second, withdrawal symptoms to overcome. You may not be able to follow Raghu Ram's seven-step guide exactly, but his story is inspiring enough to encourage people to try quitting smoking.